To address the therapeutic potential of targeting hepatic oxalate overproduction for the treatment of established MASH, we utilized our approach for inhibiting GO and LDHA using the salicylic acid derivative MDMG-935P54. This evidence concerns the gene HAO1 and metabolic dysfunction-associated steatohepatitis.